[go: up one dir, main page]

PE20091345A1 - Arilindenopirimidinas como antagonistas del receptor a2a de adenosina - Google Patents

Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Info

Publication number
PE20091345A1
PE20091345A1 PE2008001825A PE2008001825A PE20091345A1 PE 20091345 A1 PE20091345 A1 PE 20091345A1 PE 2008001825 A PE2008001825 A PE 2008001825A PE 2008001825 A PE2008001825 A PE 2008001825A PE 20091345 A1 PE20091345 A1 PE 20091345A1
Authority
PE
Peru
Prior art keywords
disease
adenosine
antagonists
arylindenopyrimidines
receptor
Prior art date
Application number
PE2008001825A
Other languages
English (en)
Inventor
Brian C Shook
Paul F Jackson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20091345A1 publication Critical patent/PE20091345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULAS A, B O C, SOLVATOS, HIDRATOS, TAUTOMEROS Y SALES FARMACEUTICAS ACEPTABLES DE ESTOS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE ADENOSINA A2A, SIENDO UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DE PARKINSON, MAL DE HUNTINGTON, ATROFIA SISTEMICA MULTIPLE, DEGENERACION CORTICOBASAL, ENFERMEDAD DE ALZHEIMER Y DEMENCIA SENIL, ENTRE OTROS
PE2008001825A 2007-10-25 2008-10-24 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina PE20091345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
PE20091345A1 true PE20091345A1 (es) 2009-09-24

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001825A PE20091345A1 (es) 2007-10-25 2008-10-24 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Country Status (13)

Country Link
US (1) US20090111804A1 (es)
EP (1) EP2220053B1 (es)
JP (1) JP2011500833A (es)
CN (1) CN101835760A (es)
AR (1) AR069026A1 (es)
AT (1) ATE509012T1 (es)
AU (1) AU2008316821A1 (es)
CL (1) CL2008003184A1 (es)
PA (1) PA8801401A1 (es)
PE (1) PE20091345A1 (es)
TW (1) TW200934496A (es)
UY (1) UY31421A1 (es)
WO (1) WO2009055548A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2326075T3 (es) * 2003-10-03 2009-09-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a.

Also Published As

Publication number Publication date
EP2220053B1 (en) 2011-05-11
AU2008316821A1 (en) 2009-04-30
AR069026A1 (es) 2009-12-23
WO2009055548A1 (en) 2009-04-30
CN101835760A (zh) 2010-09-15
CL2008003184A1 (es) 2009-10-16
PA8801401A1 (es) 2009-05-15
US20090111804A1 (en) 2009-04-30
UY31421A1 (es) 2009-04-30
TW200934496A (en) 2009-08-16
EP2220053A1 (en) 2010-08-25
JP2011500833A (ja) 2011-01-06
ATE509012T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
CO6741217A2 (es) Modulares de receptor de glucagón
HN2010001563A (es) Compuestos
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
GT201400111A (es) Triazolopiridinas sustituidas
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
GT200700024A (es) Derivados de amina
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
GT200600114A (es) Derivados de ciclopropanocarboxamida
CL2008003811A1 (es) Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor.
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
MX2016010848A (es) Ciclopentanos 1,2-sustituidos como antagonistas del receptor de la orexina.
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2018001092A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros

Legal Events

Date Code Title Description
FD Application declared void or lapsed